 CAMBRIDGE, Mass., Oct. 19, 2022 GLOBE NEWSWIRE -- Spero Therapeutics, Inc. Nasdaq: SPRO, a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant MDR bacterial infections, today announced data presentations for 7 abstracts accepted at the Infectious Disease Society of America IDSA IDWeekTM 2022, taking place from October 19 23, 2022 in Washington, DC. 